hotspot -WSS

hotspot

author：focus 2025-10-02 22:27:39 - browse：769

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

LONDON — Roche on Thursday said its recently acquired experimental obesity medication helped people lose a significant amount of weight in an early trial, sending its shares up in early trading.

The drug, a once-weekly injection known as CT-388, resulted in an average placebo-adjusted weight loss of 18.8% after 24 weeks, the company said. The study was a Phase 1 trial, though it was placebo-controlled.

The reaction to such an early result — Roche shares were up roughly 4% early Thursday — is a signal both of the stakes of the obesity medication race and the keen interest investors have in the field.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： CommonSpirit Health keeps growing, even as it loses money

WSS

A virus, fished out of a lake, may have saved a man’s life

FDA panel signals lack of confidence in Amgen cancer drug data

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Sana to lay off nearly a third of staff, de

3 questions for the future of Biden's cancer moonshot

Bill would stop addiction treatment from triggering child abuse inquiry

explore

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

Microbiome research is starting to find links to chronic diseases

Sports medicine is finally prioritizing gender equality

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Guidelines to prevent youth baseball injuries need more muscle

Emergency workers more likely to restrain Black patients: study

23andMe had bad news about my health. I wish a person had delivered it

Physician executives need more than on

The high cost of giving birth even with insurance

CDC's new outbreak response network to include Northeastern

knowledge

Senate panel eyes new effort on drug shortages

CommonSpirit Health keeps growing, even as it loses money

How Vertex's cystic fibrosis drug is changing patients' lives

A virus, fished out of a lake, may have saved a man’s life

Biotech lab space demand falls sharply

3 questions for the future of Biden's cancer moonshot

Wikipedia

Wikipedia

focus

leisure time